Lipocine Reports Positive Interim Safety Data for LPCN 1154 in Postpartum Depression Trial
ByAinvest
Wednesday, Nov 19, 2025 2:09 am ET1min read
LPCN--
Lipocine has completed an independent Data Safety Monitoring Board review of its Phase 3 trial for LPCN 1154, an oral brexanolone treatment for postpartum depression. The review found a promising interim safety profile, with no treatment discontinuations or serious adverse events reported. The trial, which is evaluating LPCN 1154 in women with severe PPD, is expected to continue without modification.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet